All High-Throughput Screening (HTS) articles – Page 13
-
WhitepaperWhitepaper: Organoids: How close are we to the clinic?
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
-
EventSLAS2023 International Conference and Exhibition
SLAS2023 invites attendees to a sold-out exhibition with more than 390 exhibitors including start-up and emerging companies in our Innovation AveNEW area.
-
WhitepaperWhitepaper: Oncology therapeutics discovery solutions
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
-
WebinarUsing integrative biophysical approaches to understand GPCR regulation by β-arrestins
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
-
ArticleArtificial intelligence: a great crash of hype into reality
Technology is infamous for falling into a hype cycle, with its peaks and valleys of exaggerated expectations and disillusionment — AI-driven drug discovery is no exception. In this article, Aaron Daugherty, Vice President Discovery at Aria Pharmaceuticals, highlights how the industry can use AI to transform research.
-
WhitepaperWhitepaper: Neurodegeneration therapeutics discovery
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
-
NewsStudy suggests existing cancer drug may be effective against non-alcoholic fatty liver disease
The researchers used single-nuclear sequencing and advanced three-dimensional glass imaging of mice to find new drug targets for non-alcoholic fatty liver disease.
-
WhitepaperGlossary: Multiplexing 101 – The essential guide
What is multiplexed immunofluorescence microscopy imaging?
-
WhitepaperPoster: Antibodies for microglial activation states
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.